ABL1 and cancer: In addition, in a BCR-ABL transgenic mouse model inhibition of SIRT1 in combination with the tyrosine kinase inhibitor Imatinib leads to p53 activation-mediated elimination of cancer stem cells, indicating that SIRT1 inhibition may represent a strategy for targeting cancer stem cells [12].